Corrigendum : The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases(Front. Immunol., (2023), 14, (1191782), 10.3389/fimmu.2023.1191782)

In the published article, there was an error in Table 1 as published. The cell corresponding to ixekizumab in HS must be yellow rather than green, since it is not approved for that indication, nor has phase 3 clinical development been published. Also, there is no data regarding clinical studies using tildrakizumab for IBD, so the color has been changed to yellow. The legend has been modified for clarification. The changes include the modification from "Green: Shown efficacy" to "Green: approved or shown efficacy in phase 3 clinical trials". The corrected Table 1 and its caption "Available therapies targeting IL-17 and IL-23 in IMIDs" appear below. Available therapies targeting IL-17 and IL-23 in IMIDs. axSpA, axial spondyloarthritis; HS, hidradenitis suppurativa; IBD, inflammatory bowel disease; IL, interleukin; PsA, psoriasis arthritis; PsO, psoriasis. *The table only includes therapies that have been approved by the European Medicines Agency (EMA) or that have published phase 3 clinical development. Green: approved or shown efficacy in phase 3 clinical trials. Red: Lack of efficacy. Yellow: Insufficient or unclear evidence. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.